Health Care • Biotechnology: Pharmaceutical Preparations
$45.23 ▼ -0.49
(-1.08%)
MKT CAP: $1.90B • VOL: 471.7K
52W L $15 52W H $50
ROARABLE / RQD
E • 33/100
PIOTROSKI
2 / 9
TRAX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 |
|---|---|---|
| Revenue (Total Sales) | $0 | $0 |
| YoY Revenue Growth % | — | — |
| Gross Profit | — | — |
| Gross Margin % | — | — |
| Research & Development (R&D) | — | — |
| Operating Income (EBIT) | -$179.0M | -$181.1M |
| Operating Margin % | — | — |
| Net Income (GAAP) | -$166.1M | -$163.7M |
| EBITDA (Normalized) | -$178.9M | -$180.8M |
| Diluted EPS ($/sh) | — | — |
| Operating Cash Flow (OCF) | -$142.9M | -$125.8M |
| Capital Expenditures (CapEx) | $87.0K | $358.0K |
| Free Cash Flow (FCF) | -$143.0M | -$126.2M |
| FCF Margin % | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% |
| Cash & Short-Term Equivalents | $238.2M | $123.1M |
| Total Debt (Short + Long Term) | — | — |
| Total Stockholders' Equity | $287.5M | $391.6M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TRAX.